A liver disease upstart with some global connections and a new R&D strategy reaps a $30M launch round
LONDON — Back when Jack O’Meara and Quin Wills were initially setting up Ochre Bio, they jumped from their home base in the UK to the US primarily so they could establish a syndicate of investors who could fund their startup as they began to explore new RNA therapies for liver diseases.
And the strategy is working fine.
Along the way, they got to know a lot of the people at Y Combinator, setting up a $10 million seed round last year that put them on track to the $30 million launch round the CEO/CSO founder team is unveiling today. Their backers now include Intellia founder Nessan Bermingham at Khosla as well as Alice Zhang, the CEO at Verge Genomics who is putting some of her own money behind Ochre.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
